236 related articles for article (PubMed ID: 22470440)
1. Induction of protective CD4+ T cell-mediated immunity by a Leishmania peptide delivered in recombinant influenza viruses.
Kedzierska K; Curtis JM; Valkenburg SA; Hatton LA; Kiu H; Doherty PC; Kedzierski L
PLoS One; 2012; 7(3):e33161. PubMed ID: 22470440
[TBL] [Abstract][Full Text] [Related]
2. TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia).
Jayakumar A; Castilho TM; Park E; Goldsmith-Pestana K; Blackwell JM; McMahon-Pratt D
PLoS Negl Trop Dis; 2011 Jun; 5(6):e1204. PubMed ID: 21695103
[TBL] [Abstract][Full Text] [Related]
3. Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania.
Dondji B; Deak E; Goldsmith-Pestana K; Perez-Jimenez E; Esteban M; Miyake S; Yamamura T; McMahon-Pratt D
Eur J Immunol; 2008 Mar; 38(3):706-19. PubMed ID: 18286565
[TBL] [Abstract][Full Text] [Related]
4. Induction of protective cellular immune responses against experimental visceral leishmaniasis mediated by dendritic cells pulsed with the N-terminal domain of Leishmania infantum elongation factor-2 and CpG oligodeoxynucleotides.
Agallou M; Pantazi E; Tsiftsaki E; Toubanaki DK; Gaitanaki C; Smirlis D; Karagouni E
Mol Immunol; 2018 Nov; 103():7-20. PubMed ID: 30173073
[TBL] [Abstract][Full Text] [Related]
5. A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis.
Carson C; Antoniou M; Ruiz-Argüello MB; Alcami A; Christodoulou V; Messaritakis I; Blackwell JM; Courtenay O
Vaccine; 2009 Feb; 27(7):1080-6. PubMed ID: 19095029
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.
Zanin FH; Coelho EA; Tavares CA; Marques-da-Silva EA; Silva Costa MM; Rezende SA; Gazzinelli RT; Fernandes AP
Microbes Infect; 2007 Jul; 9(9):1070-7. PubMed ID: 17644455
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
Gurunathan S; Sacks DL; Brown DR; Reiner SL; Charest H; Glaichenhaus N; Seder RA
J Exp Med; 1997 Oct; 186(7):1137-47. PubMed ID: 9314562
[TBL] [Abstract][Full Text] [Related]
8. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.
Saljoughian N; Zahedifard F; Doroud D; Doustdari F; Vasei M; Papadopoulou B; Rafati S
Parasite Immunol; 2013 Dec; 35(12):397-408. PubMed ID: 23710803
[TBL] [Abstract][Full Text] [Related]
9. A lentiviral vaccine expressing KMP11-HASPB fusion protein increases immune response to Leishmania major in BALB/C.
Mortazavidehkordi N; Fallah A; Abdollahi A; Kia V; Khanahmad H; Najafabadi ZG; Hashemi N; Estiri B; Roudbari Z; Najafi A; Farjadfar A; Hejazi SH
Parasitol Res; 2018 Jul; 117(7):2265-2273. PubMed ID: 29845415
[TBL] [Abstract][Full Text] [Related]
10. A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis.
Oliveira-da-Silva JA; Machado AS; Ramos FF; Tavares GSV; Lage DP; Mendonça DVC; Pereira IAG; Santos TTO; Martins VT; Carvalho LM; Freitas CS; Ludolf F; Reis TAR; Bandeira RS; Silva AM; Costa LE; Oliveira JS; Duarte MC; Roatt BM; Teixeira AL; Coelho EAF
Cell Immunol; 2020 Oct; 356():104194. PubMed ID: 32827943
[TBL] [Abstract][Full Text] [Related]
11. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani.
Guha R; Das S; Ghosh J; Naskar K; Mandala A; Sundar S; Dujardin JC; Roy S
Vaccine; 2013 Apr; 31(15):1905-15. PubMed ID: 23499564
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a new live recombinant vaccine against cutaneous leishmaniasis in BALB/c mice.
Salari S; Sharifi I; Keyhani AR; Ghasemi Nejad Almani P
Parasit Vectors; 2020 Aug; 13(1):415. PubMed ID: 32787908
[TBL] [Abstract][Full Text] [Related]
13. High quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK/MVA-LACK regimen in Leishmania major BALB/c model of infection.
Sánchez-Sampedro L; Gómez CE; Mejías-Pérez E; Sorzano CO; Esteban M
PLoS One; 2012; 7(6):e38859. PubMed ID: 22715418
[TBL] [Abstract][Full Text] [Related]
14. IFN-γ
Yadav S; Prakash J; Singh OP; Gedda MR; Chauhan SB; Sundar S; Dubey VK
Cell Immunol; 2021 Mar; 361():104272. PubMed ID: 33445051
[TBL] [Abstract][Full Text] [Related]
15. DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice.
Ahmed SB; Touihri L; Chtourou Y; Dellagi K; Bahloul C
Vaccine; 2009 Jan; 27(1):99-106. PubMed ID: 18951941
[TBL] [Abstract][Full Text] [Related]
16. Enhanced protective efficacy of nonpathogenic recombinant leishmania tarentolae expressing cysteine proteinases combined with a sand fly salivary antigen.
Zahedifard F; Gholami E; Taheri T; Taslimi Y; Doustdari F; Seyed N; Torkashvand F; Meneses C; Papadopoulou B; Kamhawi S; Valenzuela JG; Rafati S
PLoS Negl Trop Dis; 2014 Mar; 8(3):e2751. PubMed ID: 24675711
[TBL] [Abstract][Full Text] [Related]
17. Antigenicity of
Fernández L; Carrillo E; Sánchez-Sampedro L; Sánchez C; Ibarra-Meneses AV; Jimenez MA; Almeida VDA; Esteban M; Moreno J
Front Immunol; 2018; 9():843. PubMed ID: 29740446
[No Abstract] [Full Text] [Related]
18. MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis.
Pérez-Jiménez E; Kochan G; Gherardi MM; Esteban M
Microbes Infect; 2006 Mar; 8(3):810-22. PubMed ID: 16504562
[TBL] [Abstract][Full Text] [Related]
19. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
Melby PC; Yang J; Zhao W; Perez LE; Cheng J
Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
[TBL] [Abstract][Full Text] [Related]
20. Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells.
Gurunathan S; Stobie L; Prussin C; Sacks DL; Glaichenhaus N; Iwasaki A; Fowell DJ; Locksley RM; Chang JT; Wu CY; Seder RA
J Immunol; 2000 Jul; 165(2):915-24. PubMed ID: 10878366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
